Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

33.47USD
19 Jan 2017
Change (% chg)

$-0.63 (-1.85%)
Prev Close
$34.10
Open
$33.98
Day's High
$34.09
Day's Low
$33.46
Volume
1,970,078
Avg. Vol
1,877,503
52-wk High
$64.31
52-wk Low
$33.46

Latest Key Developments (Source: Significant Developments)

U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta
Thursday, 12 Jan 2017 10:16am EST 

U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling : U.S. Court of appeals for the federal circuit upholds lower court finding that teva was liable for inducing infringement by doctors Further company coverage: [LLY.N].  Full Article

Teva reaches settlement with government on FCPA
Thursday, 22 Dec 2016 09:15am EST 

Teva Pharmaceutical Industries Ltd : Teva reaches settlement with government on FCPA . Teva Pharmaceutical - co, DoJ and sec have agreed to a resolution to resolve previously disclosed investigations into conduct relating to three countries . Resolution also includes previously reserved payments totaling $519 million . Conclusion of negotiations with united states government over violations of foreign corrupt practices act . Teva Pharmaceutical industries - resolution includes a deferred prosecution agreement, implementation of a temporary independent compliance monitor . Teva Pharmaceutical - to resolve previously disclosed investigations into conduct relating to 3 countries - Ukraine, Mexico and a guilty plea by unit in Russia .Teva Pharmaceutical industries- resolution involves conduct occurring in past, and none of the employees involved in improper payments are still employed.  Full Article

Teva, IBM to enable drug development and chronic disease management with Watson
Wednesday, 26 Oct 2016 07:00am EDT 

International Business Machines Corp: Teva Pharmaceuticals and IBM expand global partnership to enable drug development and chronic disease management with Watson . IBM - collaboration features first integration of weather company data with IBM Watson health cloud . IBM - projects will run on IBM Watson health cloud . IBM - expanded partnership features three-year research collaboration to develop cognitive technologies .IBM - companies announced that respiratory and central nervous system diseases will be first targets for chronic disease management initiative.  Full Article

Teva and Celltrion report exclusive biosimilar commercial partnership
Thursday, 6 Oct 2016 08:00am EDT 

Teva Pharmaceutical Industries Ltd : Teva will pay Celltrion healthcare $160 million upfront . Teva and Celltrion healthcare will share profit from commercialization of mab biosimilars . Exclusive partnership to commercialize two of Celltrion's MAB biosimilar candidates in U.S. and canada . Celltrion has responsibility for completing all clinical development and regulatory activities .Of $160 million upfront payment, up to $60 million is refundable or creditable under certain circumstances.  Full Article

Teva announces sale of UK and Ireland actavis assets and operations
Wednesday, 5 Oct 2016 11:00am EDT 

Teva Pharmaceutical Industries Ltd : Teva announces sale of UK and Ireland actavis assets and operations . Deal for GBP 603 million . Sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England . Teva retains a number of actavis non-overlapping generic products plus certain specialty medicines and otc products . Greenhill & Co. are serving as financial advisors to Teva, and Pinsent Masons are serving as legal counsel to Teva in respect of this transaction .Divestment of certain specified actavis generics assets and operations in UK and Ireland was part of an undertaking that Teva made to European commission.  Full Article

U.S. court rules in favor of Depomed in its patent litigation for NUCYNTA
Friday, 30 Sep 2016 03:55pm EDT 

Depomed Inc : Depomed prevails in Nucynta franchise ANDA litigation providing market exclusivity until December 2025 . Company intends to appeal court's finding as it relates to infringement of '130 patent . Depomed inc says '130 patent covers Nucynta ER until March 2029 . Court found U.S. patent nos. 7,994,364 and RE39,593 to be valid and infringed by defendants . With court's ruling, Depomed expects market exclusivity until december 2025 for Nucynta ER, Nucynta and Nucynta oral solution .Judge ruled in favor of depomed in company's patent litigation against all three filers of abbreviated new drug applications for Nucynta.  Full Article

Regeneron, Teva collaborate to develop, commercialize Fasinumab
Tuesday, 20 Sep 2016 07:00am EDT 

Regeneron Pharmaceuticals Inc : Regeneron and Teva announce global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain . Teva to pay co $250 million upfront and share equally in global commercial value, and ongoing research and development costs of about $1 billion .Regeneron is eligible to receive development and regulatory milestone payments and additional payments based on net sales.  Full Article

MDxHealth and Teva Pharmaceuticals sign distribution deal
Wednesday, 31 Aug 2016 01:06am EDT 

Mdxhealth SA : MDxHealth and Teva Pharmaceuticals sign distribution agreement for SelectMDx in Israel .Teva Pharmaceuticals will be exclusive distributor of selectMDx for prostate cancer test in Israel.  Full Article

Moody's says Teva's loss of two copaxone patents is credit negative
Thursday, 25 Aug 2016 02:33pm EDT 

Moody's Ratings : Teva's loss of two copaxone patents is credit negative .Moody's on Teva Pharmaceutical - there is no change to Teva Pharmaceutical Industries LTD Baa2 senior unsecured rating or stable outlook.  Full Article

Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone
Wednesday, 24 Aug 2016 05:46pm EDT 

Teva Pharmaceutical Industries Ltd : Teva confirms PTAB's decisions on two patents in IPR challenge to Copaxone 40 mg .Teva plans to appeal to United States Court of appeals for Federal Circuit.  Full Article

BRIEF-Teva receives FDA approval for VANTRELATM ER

* Teva receives FDA approval for VANTRELATM ER (hydrocodone bitartrate) extended-release tablets formulated with proprietary abuse deterrence technology Source text for Eikon: Further company coverage: